Document is current
Any future updates will be listed below
-
Authors
Autaa, Gaëlle
Korenkov, Daniil
van Beek, Josine
Pellegrin, Isabelle
Parfait, Béatrice
van Baarle, Debbie
Launay, Odile
Tartour, Eric
Appay, Victor
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative 2 Joint Undertaking (806776, 806776, 806776, 806776)
University of Bordeaux (Senior IdEx Chair, Senior IdEx Chair)
Agence Nationale de la Recherche (ANR-21-CE15-0037, ANR-21-CE15-0037)
Ministerie van Volksgezondheid, Welzijn en Sport (VITAL, VITAL, VITAL)
Assistance Publique - Hôpitaux de Paris (CoviCompare study, CoviCompare study, CoviCompare study, CoviCompare study, CoviCompare study)
- License Information
-
More Information
Article History
Received: 10 July 2025
Accepted: 17 September 2025
First Online: 31 October 2025
Declarations
:
: The CoviCompare M and VITAL studies were approved by Comité De Protection des Personnes Ile De France (ClinicalTrials.gov NCT04748471) and by the Medical Research Ethics Committee Utrecht (EU Clinical Trials Registration 2019–000836–24), respectively. This study was performed according to Good Clinical Practice, the Declaration of Helsinki, and written informed consent was obtained from all participants.
: Not applicable.
: The authors declare no competing interests.
: The authors declare that they have no competing financial interests.
